A team of researchers from ETH-Zürich is looking for investment for their spin-off company, XpresSys, to commercialise novel protein expression technology. The technology has the potential to revolutionise screening process for new drugs.
It may have started from a low base, but the Indian biotech industry is hurtling past the global growth rate. And overseas companies are anxious to get in on the action.
The international treaty on plant genetic resources needs a gesture of trust to repair the atmosphere of suspicion that has developed, argues Emile Frison from the International Plant Genetic Resources Institute.
Biology Information Open Source's promoter, Richard Jefferson, asserts that BIOS is explicitly modelled after the Open Source initiative in software. But science is grounded in open exchange and the sharing of information, so what is the point of BIOS and other initiatives such as Science Commons?
In an earlier blog, I deplored the lack of data about the European IP market and in particular about the academic licensing business. I am delighted to report that my “bottle in the ocean” approach has produced results.
Active Solar Buildings – entirely heated and cooled by solar thermal energy – should become the standard by 2030 if the vision of the EU’s latest Technology Platform is realised.
A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.